Clinical Trial Update: Phase III Trial to Investigate Efficacy and Safety of Vilobelimab in Ulcerative Pyoderma Gangrenosum [Phase 3]

View source ↗

Summary

A Phase III trial evaluating vilobelimab for ulcerative pyoderma gangrenosum has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pyoderma Gangrenosum

Drugs mentioned

• Vilobelimab (vilobelimab)

Snippet

Sponsor: InflaRx GmbH | Conditions: Pyoderma Gangrenosum | Phase 3 | Status: TERMINATED